Masimo Co. (NASDAQ:MASI) Stake Cut by Schroder Investment Management Group

Schroder Investment Management Group trimmed its stake in Masimo Co. (NASDAQ:MASI - Free Report) by 22.7% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 566,469 shares of the medical equipment provider's stock after selling 166,152 shares during the quarter. Schroder Investment Management Group owned about 1.06% of Masimo worth $95,501,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Jones Financial Companies Lllp purchased a new stake in shares of Masimo during the 4th quarter valued at $27,000. UMB Bank n.a. boosted its holdings in Masimo by 180.9% in the fourth quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider's stock valued at $32,000 after acquiring an additional 123 shares during the last quarter. Trust Co. of Vermont purchased a new stake in Masimo during the fourth quarter valued at about $33,000. Blue Trust Inc. grew its position in Masimo by 56.3% during the fourth quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider's stock valued at $33,000 after acquiring an additional 71 shares during the period. Finally, EverSource Wealth Advisors LLC increased its stake in Masimo by 40.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider's stock worth $37,000 after acquiring an additional 64 shares during the last quarter. Institutional investors and hedge funds own 85.96% of the company's stock.

Masimo Stock Up 0.6 %

NASDAQ:MASI traded up $1.01 during trading hours on Tuesday, hitting $167.61. The stock had a trading volume of 373,879 shares, compared to its average volume of 639,303. The company has a market cap of $9.06 billion, a PE ratio of 115.59 and a beta of 1.04. The business has a 50 day simple moving average of $174.50 and a two-hundred day simple moving average of $162.48. Masimo Co. has a 1-year low of $101.61 and a 1-year high of $194.88. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50.

Remove Ads

Masimo (NASDAQ:MASI - Get Free Report) last announced its earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.42 by $0.38. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The company had revenue of $600.70 million during the quarter, compared to the consensus estimate of $593.35 million. Analysts predict that Masimo Co. will post 4.1 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on MASI shares. Piper Sandler boosted their target price on Masimo from $210.00 to $215.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. Raymond James lifted their price target on shares of Masimo from $170.00 to $194.00 and gave the company an "outperform" rating in a research report on Friday, December 27th. Wells Fargo & Company increased their price objective on shares of Masimo from $193.00 to $205.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Masimo in a research note on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $194.80.

Insiders Place Their Bets

In other news, COO Bilal Muhsin sold 30,000 shares of the firm's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $167.49, for a total transaction of $5,024,700.00. Following the completion of the sale, the chief operating officer now owns 24,172 shares of the company's stock, valued at approximately $4,048,568.28. This trade represents a 55.38 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Craig B. Reynolds sold 2,053 shares of the stock in a transaction on Friday, March 14th. The shares were sold at an average price of $166.13, for a total transaction of $341,064.89. Following the transaction, the director now owns 16,581 shares in the company, valued at $2,754,601.53. This trade represents a 11.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 9.70% of the stock is owned by company insiders.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.